CRC
54
15
19
16
Key Insights
Highlights
Success Rate
76% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
9.3%
5 terminated out of 54 trials
76.2%
-10.4% vs benchmark
2%
1 trials in Phase 3/4
63%
10 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 16 completed trials
Clinical Trials (54)
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Colon Health Champion Program
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of CBI-1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI-L Colorectal Cancer
Addition of Antibiotics to Upfront Treatment Regimen for Colorectal Cancer
Recombinant Vaccinia Virus Administered Intravenously in Patients With Metastatic, Refractory Colorectal Carcinoma
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
A Study of a Urine Test to Detect Colorectal Cancer
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Noninvasive Early Diagnosis of Colorectal Cancer Using Odor-Targeted Capture, Point-of-Care Testing, and Intelligent Analysis
Intratumoral Budding (ITB) in Preoperative Biopsies of Colon and Rectal Cancer
A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients.
Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM
Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors